Red Queen Bio Raises $36M to Combat Viral Threats with AI-Designed Antibodies

Red Queen Bio, a biosecurity startup spun out of HelixNano, has raised $36 million to develop AI-designed antibody drugs targeting viral threats like bird flu and coronaviruses. The funding round, led by OpenAI, highlights the growing role of artificial intelligence in biosecurity and pandemic preparedness.

AI-Driven Antibody Development

Red Queen Bio, a biosecurity startup, has raised $36 million to develop antibody drugs using artificial intelligence. According to The Next Web, the company designs antibodies that bind tightly to viral targets, including those that could emerge with the help of AI systems. The process involves using AI to generate antibody candidates, which are then produced and tested in the lab. Results from these tests are fed back into the AI models to refine and improve the designs.

Targeting Viral Threats

The startup is initially focusing on antibodies against bird flu and other influenza viruses. According to The Next Web, Red Queen Bio also plans to target coronaviruses, Ebola-like viruses, and relatives of smallpox in later stages. The company’s first clinical trials are scheduled for 2027, with a focus on addressing both current and future viral threats, including those that could arise from AI advancements.

Funding and Origins

OpenAI led Red Queen Bio’s $15 million seed round, with additional funding from investors such as Cerberus Ventures, Fifty Years, and Halcyon Futures. The startup was spun out of HelixNano in 2025 by Nikolai Eroshenko, chief executive, and Hannu Rajaniemi, executive director. Red Queen Bio has emphasized that it does not conduct gain-of-function research or handle dangerous pathogens.

Broader Biosecurity Context

Red Queen Bio’s work reflects a wider effort to address biosecurity risks posed by AI. According to The Next Web, Google DeepMind launched an AI biosecurity program in July, while a Cisco study found that no existing AI model is fully resistant to bioweapon-related queries. Dario Amodei, linked to Anthropic, has publicly called for a UN-backed ban on AI bioweapons, underscoring the urgency of the issue.

AI and Biosecurity: Broader Trends

The intersection of AI and biosecurity is gaining traction as companies explore how machine learning can accelerate drug discovery while mitigating risks. For example, debates continue about AI’s role in scientific breakthroughs, such as Anthropic’s claim that its AI identified a DNA sequence pattern—a claim biologists argue overlooks human contributions. Red Queen Bio’s approach demonstrates a more targeted use of AI, focusing on actionable solutions for viral threats rather than theoretical discoveries.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Red Queen Bio’s funding round highlights a critical shift in how startups are addressing biosecurity risks—using AI not just for discovery but as a defensive tool against viral threats. For founders, this signals a growing appetite for preventive biotech solutions, particularly those that leverage AI to accelerate development without crossing ethical red lines like gain-of-function research.

The involvement of OpenAI and other high-profile investors also reflects a broader trend: tech leaders are increasingly investing in biosecurity as a hedge against risks posed by their own advancements. If Red Queen Bio succeeds in its 2027 trials, it could validate a model where AI-driven biotech startups prioritize readiness over reaction, potentially reshaping how the industry approaches pandemic preparedness.

Key takeaways

• Red Queen Bio has raised $36 million in total funding to develop AI-designed antibody drugs.
• The startup targets viral threats like bird flu, coronaviruses, and Ebola-like viruses, with clinical trials planned for 2027.
• OpenAI led a $15 million seed round, with participation from Cerberus Ventures, Fifty Years, and Halcyon Futures.
• Red Queen Bio uses AI to design antibodies and avoids gain-of-function research or handling dangerous pathogens.
• The company was spun out of HelixNano in 2025 and aligns with broader biosecurity efforts in AI.

FAQ

What is Red Queen Bio’s primary focus?

Red Queen Bio uses AI to design antibody drugs targeting viral threats, including bird flu, coronaviruses, and Ebola-like viruses. The goal is to create treatments for both existing and potential future pandemics.

Who invested in Red Queen Bio?

OpenAI led the startup’s $15 million seed round, with additional funding from Cerberus Ventures, Fifty Years, and Halcyon Futures. The total funding raised is $36 million.

When will Red Queen Bio begin clinical trials?

The company plans to start its first clinical trials in 2027.

Does Red Queen Bio conduct gain-of-function research?

No. The company has stated that it does not conduct gain-of-function research or handle dangerous pathogens.

How does AI help Red Queen Bio’s work?

AI is used to design and refine antibodies by simulating how they bind to viral targets. Lab tests then provide data to improve the AI models, creating a feedback loop for optimization.

Related on Lazyfounder

• OpenAI
• Anthropic
• More startup news
• Scientists Challenge Anthropic’s Claim of AI-Made Discovery